Please assess the completion status of the following clinical trial:

Trial Title: The Effect of Raltegravir on HIV Decay During Primary and Chronic Infection

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Age at least 18 years.~* Provision of written, informed consent.~* Screening plasma HIV RNA \> 10,000 copies/mL.~* Screening CD4+ T lymphocyte count \> 100 x 10\^6)/L.~* No previous antiretroviral therapy.~* Haemoglobin \> 115 g/L (female) or \> 130 g/L (male).~* Absolute neutrophil count \> 1 x 10\^9/L.~* Platelet count \> 100 x 10\^9/L~* Serum bilirubin \< 1.5 x ULN.~* Serum alkaline phosphatase \< 3 X ULN.~* Serum aspartate aminotransferase (AST) \< 3 X ULN.~* Serum alanine aminotransferase (ALT) \< 3 X ULN.~* Creatinine clearance \> 50mL/min (Creatinine clearance (mL/min) =140 - age x weight creatinine Multiply the result by 1.2 for men).~Cohort A: Primary HIV infection:~Documented acute or early infection diagnosed by:~Acute infection:~\< 3 bands on Western Blot and any one of: i. positive p24 antigen ii. positive proviral DNA~Early infection:~i. Positive detuned or BED ELISA result OR ii. Previously negative serology within 6 months of confirmed positive serology.~Cohort B: Chronic HIV infection:~Documented HIV-infection of at least 12 months duration.~Exclusion Criteria:~* Pregnancy or breastfeeding.~* Receipt of investigational products within 1 month of study entry.~* Receipt of any of the following within 6 months of study entry:~  * interferon alpha or gamma~ * oral corticosteroids (inhaled or topical corticosteroids are permitted)~ * cyclosporin~ * alkylating agents~ * other immunosuppressive agents~ * rifampin~ * phenytoin~ * phenobarbital~* Documented genotypic (IAS 2007) resistance to tenofovir or emtricitabine from any HIV drug resistance test.~* Any medications contraindicated with Truvada or raltegravir.~* Significant intercurrent illnesses apart from HIV infection such as viral hepatitis (diagnosed by core hepatitis B antigen and/or positive hepatitis B PCR or positive hepatitis C PCR) or any other condition which in the opinion of the investigator would compromise participation in the study.~* History of non-traumatic osteoporotic fracture.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- antiretroviral therapy (Type: EXPERIMENTAL): tenofovir (TDF) + emtricitabine (FTC) as a fixed dose combination administered orally once per day and raltegravir (RAL) administered orally twice per day.

Based on this trial design, predict the completion outcome and termination type (if applicable).